Drawing for PHARMACUBE

USPTO serial 99393610

PHARMACUBE

Reviewed by CopyMark Law Group

Status 730Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
MCMORROW, JANICE LEE
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 730: Status 730 means you filed the first six-month extension to delay filing a Statement of Use after a Notice of Allowance. You must file a Statement of Use or another extension before the new deadline.

Need help with PHARMACUBE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*

Plus Government fees of $150

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Theresa A Gresl

Theresa A Gresl Schiehallion IP Consulting LLC6709 Raymond Rd. Suite 232Madison, WI 53719United States

Goods and services

ClassDescriptionStatusFirst use
035Retail store services featuring health and beauty products, medications, and supplements; On-line retail store services featuring health and beauty products, medications, and supplements; Providing purchase advisory and consulting services to consumers for the purchase of health and beauty products, medications, and supplementsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 21, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 21, 2026EX1GSOU EXTENSION 1 GRANTED—
Oct 20, 2026EXT1SOU EXTENSION 1 FILED—
Oct 20, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 15, 2026EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Oct 15, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 15, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 15, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 5, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 5, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jun 5, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 28, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 3, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 3, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 25, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 10, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 9, 2026DOCKASSIGNED TO EXAMINER—
Feb 8, 2026MDSMNOTICE OF DESIGN SEARCH CODE E-MAILED—
Feb 8, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 15, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 15, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance